INBP — Integrated Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $5.44m
- $1.08m
- $43.87m
Annual cashflow statement for Integrated Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3.84 | -0.034 | 0.112 | 0.808 | -2.84 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.882 | 1.15 | 1.13 | 1.18 | 1.32 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.565 | -0.302 | -0.744 | -1.5 | 2.21 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 4.09 | 1.23 | 0.943 | 2.06 | 1.24 |
| Capital Expenditures | -0.486 | -0.116 | -0.553 | -0.205 | -0.346 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.021 | 0.005 | 0 | — | 0.006 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -0.465 | -0.111 | -0.553 | -0.205 | -0.34 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3.5 | -0.136 | -0.029 | 0.078 | -0.045 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.121 | 0.985 | 0.361 | 1.94 | 0.856 |